|Home | About | Journals | Submit | Contact Us | Français|
Recoverin has been demonstrated to be one of the main causative antigenic retinal proteins common in many cases of autoimmune retinopathy (AIR). Strategies for producing two different AIR mouse models associated with anti-recoverin antibodies were tested.
(1) Six-week-old female B6.MRL-Fallpr/J mice (LPR) mice were immunized with recombinant recoverin three times at 2–4 week intervals. (2) Five-month-old Balb/cJ mice were injected with hybridoma cells designed to produce recoverin monoclonal antibodies. Anti-recoverin antibodies were analyzed by immunoblot and enzyme-linked immunosorbent assay (ELISA). Electroretinograms (ERG), histopathologic examination, and flow cytometric analysis were assessed.
High anti-recoverin antibody levels were achieved in both models, accompanied by significantly reduced scotopic and photopic responses on the ERGs. Retinal histology showed swollen cell bodies in the inner nuclear layer in recoverin-immunized LPR mice, while photoreceptor and outer nuclear layer swelling was observed in recoverin hybridoma cells injected into balb/cJ mice. Glial fibrillary acidic protein (GFAP) staining detected a marked increase of Müller cells and astrocyte reactive gliosis in both mouse models. Rhodopsin and S-opsin staining was similar to controls, while decreased numbers of bipolar cells were observed in both models. Complement component C1q and C3 deposits increased upon immunohistopathologic retinal staining in both models, while increased numbers of CD4+ and CD68+ cells from retinas were found upon flow cytometric analysis.
These two models had similar pathology in the retina, indicating the retinal antigens to recoverin antibody set off pathologic events that include leukocyte invasion, complement deposition, reactive gliosis in the retina, and selective retinal degeneration of inner nuclear layer neurons. These two AIR mouse models will allow for detailed pathologic investigation and testing of protein antigens associated with human AIR and can be used to test treatments. It is important to note that, since most AIR patients have multiple anti-retinal antibodies, it will be possible to study which antibodies are pathologic and which have no retinal pathologic effects. These models can also serve as an important research resource for studying the pathophysiology of specific retinal proteins by creating autoantibodies, which potentially will give a better understanding of retinal protein interactions.
Autoimmune retinopathy (AIR) is an ophthalmologic disease characterized by sudden and progressive loss of vision in association with circulating anti-retinal autoantibodies (ARAs). The condition may occur as a primary autoimmune condition or in association with various cancers. Three forms have been reported over the last 15–20 years, including cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), and non-paraneoplastic AIR (npAIR) [1-3]. Complicating the understanding of AIR are cases that have a secondary complication occurring in other disorders such as retinitis pigmentosa or birdshot retinopathy, meaning there can be several clinical manifestations related to anti-retinal antibodies [4,5]. Most AIR patients do not have a previous history of visual problems or night blindness until they suddenly develop the onset of photopsias, followed by other symptoms such as night blindness, scotomata, and visual field loss. No discernible retinal changes are initially seen upon fundus examination. However, standardized electroretinography (ERG) will show abnormal responses. Many patients also have negative waveforms on dark-adapted bright flash testing, which, along with the constellation of the above symptoms and findings, is a hallmark of the disease . Most patients do not have pigmentary deposits, but exhibit a diffuse hypopigmented atrophic retinopathy. Autoimmune retinopathy typically occurs without any sign of anterior or posterior uveitis (cells or flare upon biomicroscopy). A few AIR cases may show retinal vascular sheathing [7,8]. While AIR patients typically have these common clinical features, no uniform set of ARAs have been found to be circulating in these patients; typically AIR patients have three to six different ARAs found on immunoblots, and the number of bands and intensity of staining is stronger in affected patients compared to normal control samples. In general, AIR is treatable with immunosuppression therapies [1,9]. Currently, most immunoreactive bands on west blot represent unknown retinal proteins. Many of the known antigenic retinal proteins with pathologic associations have not been widely investigated for lack of a good animal model system.
Autoantibodies against various retinal proteins, including recoverin, α-enolase, transducin-α, S-arrestin, heat shock proteins, carbonic anhydrase II (CA II), aldolase A, aldolase C, TULP-1, and others have been found in patients with AIR [1,10,11]. We identified anti-recoverin and six other antibodies in several patients with MAR using proteomic analysis [1,10,11]. For about a decade, it was believed that recoverin, often referred to as the CAR antigen, was the sole autoantigen involved in the development of CAR. Anti-recoverin antibodies have been used to diagnose CAR, but other cancer-associated antibodies have also been found [3,10,12-14]. Patients with CAR have loss of both rods and cones, indicating widespread retinal dysfunction [15,16].
The protein recoverin is found in photoreceptor and retinal bipolar cells and is a Ca2+-binding protein that plays a regulatory role in phototransduction . When Lewis rats were immunized with recoverin, it induced uveoretinitis , which is not a feature of AIR where patients do not have cell or flare clinically. When anti-recoverin antibody was injected intravitreally into anesthetized monkey, rat, and rabibit eyes, the antibody caused retinal cell death by apoptosis in vivo  and in vitro [19,20].
To better understand the role of anti-recoverin antibodies in AIR, we first tried immunizing C57BL/6J mice with recoverin, but found minimal expression of anti-recoverin antibody and no ERG changes. We chose B6.MRL-Faslpr/J mice (LPR) for immunization with recoverin because upon screening twenty mouse strains for anti-retinal antibodies it was the only strain in which we found naturally occurring (faint) anti-retinal antibodies (data not shown). B6.MRL-Faslpr/J mice have a lymphoproliferation spontaneous mutation (Faslpr) that show systemic autoimmunity and are regarded as a mouse model for lupus . We chose this strain to investigate if an AIR model could be induced by immunization with recoverin. A second approach in our search for murine models of AIR was to create recoverin-sensitized hybridoma cells and then to implant the hybridoma cells in balb/cJ mice. This approach allowed us to examine if high levels of circulating anti-recoverin antibody would produce a retinopathy.
All studies involving mice were approved by the University Committee on the Use and Care of Animals at the University of Michigan. B6.MRL-Faslpr/J (LPR) mice, C57BL/6J mice, and balb/cJ mice were obtained from Jackson Laboratory, Bar Harbor, ME. Sample sizes of six for each group were chosen due to the scarcity of recoverin protein for immunization.
A mouse recoverin-expressing construct was made in pET11a-Rec (kindly provided by Dr. James Hurley). Recombinant recoverin was purified as described previously . Briefly, a recoverin construct was transformed and expressed in E. coli strain BL21 (DE3) pLysS (Novagen, Merck, Darmstadt, Germany). The culture was grown in 250 ml of LB (Luria–Bertani) medium at 37 °C containing ampicillin (50 μg/ml). Protein expression was induced with 1 mM isopropyl α-d-thiogalactopyranoside and cells were incubated for an additional 3 h at room temperature. Cells were then harvested by centrifugation and re-suspended in 10 ml of buffer A (50 mM Hepes (pH 7.5), 100 mM NaCl, 1 mM CaCl2, 5 mM α-mercaptoethanol, and 0.1 mM PMSF). After sonication and centrifugation (20,000× g for 30 min at 4 °C), the cleared lysate was loaded onto a buffer A-preequilibrated Econ-column (10 mm id×10 cm; Bio-Rad, Hercules, CA) with 5 ml of Phenyl Sepharose 6 Fast Flow (low sub resin; Amersham Biosciences, GE healthcare, Piscataway, NJ) at a flow rate of 0.4 m/min. The column was washed (2 ml/min) with at least 10 column volumes of buffer A to remove nonspecifically adsorbed proteins. Fractions of purified recoverin were eluted (0.4 ml/min) with buffer B (5 mM Hepes pH 7.5, 100 mM NaCl, 5 mM α-mercaptoethanol, and 5 mM EGTA) and stored at −70 °C until use.
Six-week-old balb/cJ mice were used for hybridoma production. In brief, 50 μg recoverin protein in 200 µl of PBS or 200 µl of PBS (for control mice) were mixed with equal volumes of Complete Freund's adjuvant (Pierce, Rockford, IL). The mixed emulsion was injected intraperitoneally on day 0; a second dose of 50 µg recoverin protein in an emulsion with Incomplete Freund's adjuvant (Pierce) was injected intraperitoneally on days 14 and 42. When the serum antibody titer reached twice the background value at 1:10,000 dilution, single spleen cells from the immunized mice were fused with previously prepared myeloma cells . Fusion is accomplished by co-centrifuging freshly harvested spleen and myeloma cells in the presence of polyethylene glycol. The cells were then distributed to 96-well plates containing feeder cells. The newly formed small clusters of hybridoma cells from the 96-well plates were then grown in tissue culture flasks and clone screening was performed to determine which cultures were producing recoverin antibodies.
Six-week-old LPR mice or C57BL/6J mice were injected intraperitoneally with 50 µg recoverin (n=6) or PBS (n=6; control mice) in an emulsion with Complete Freund's adjuvant containing Mycobacterium tuberculosis (1:1, v/v; Pierce) on day 0; 50 µg protein in an emulsion with Incomplete Freund's adjuvant (1:1, v/v; Pierce) were injected intraperitoneally on days 14 and 42. On day 49, tail blood was taken using capillary tubes (Sarstedt, Numbrecht, Germany), ERGs were recorded, and the mouse eyes were enucleated after euthanasia (ketamine [80 mg/kg] and xylazine [16 mg/kg]) for histopathologic examination and flow cytometric analysis.
Five-month-old balb/cJ mice were given pristane (500 μl) two weeks before the intraperitoneal injection of hybridoma cells (5×106 cells; n=6). Ascites formed 7–10 days after the injection and were withdrawn for antibody testing. Next, ERGs were recorded and the mice eyes were taken as above for histology.
Mice were dark-adapted overnight and anesthetized with an intraperitoneal injection of normal saline solution containing ketamine (80 mg/kg) and xylazine (16 mg/kg). Next, ERGs were recorded from the corneal surface after pupil dilation (0.1% atropine and 0.1% phenylephrine HCl) using a gold loop electrode referenced to a gold wire in the mouth. An electrode placed in the tail served as a ground. A drop of methylcellulose (2.5%) was placed on the corneal surface to ensure electrical contact and to maintain corneal integrity. Body temperature was maintained at a constant temperature of 38 °C using a heated water pad. All stimuli were presented in a Ganzfeld dome (LKC Technologies, Gaithersburg, MD). Rod-dominated responses to white flashes of light over a 4.0–5.0 log unit range of intensities were recorded. Cone-dominated responses were obtained with white flashes over a 2.0 log unit range of intensities at 2.1 Hz on a rod-saturating background (1.46 log cd/m2) after 10 min of exposure to the background light to allow for complete light adaptation. Responses were amplified and filtered (0.03–10,000 Hz) and digitized using an I/O board (model PCI-1200; National Instruments, Austin, TX) in a personal computer. Evoked responses were sampled every 0.5 ms over a response window of 240 ms. For each stimulus condition, responses were computer-averaged with up to 20 records averaged for the weakest signals.
Purified recoverin (0.2 µg) was applied to 4%–20% linear gradient Tris–HCl gel (Bio-Rad) and transferred onto nitrocellulose membranes (Bio-Rrad). The membranes were blocked with 5% milk and incubated with samples of analyzed sera diluted 1:1,000. Immune complexes were detected with anti-mouse IgG goat horseradish peroxidase-conjugated secondary antibodies (SouthernBiotech, Birmingham, AL) and enhanced with chemiluminescent substrate (Pierce).
Serum antibodies to recoverin were quantified by enzyme-linked immunosorbent assay (ELISA). Briefly, microtiter plates were coated with 100 ng/well of recoverin in 0.1 M Tris-HCl buffer, pH 9.0, overnight at room temperature. Following five washes with phosphate buffer solution (PBS), the plates were coated with 1% skim milk in PBS for 2 h at room temperature and then were incubated with 50 μl of diluted serum in PBS for 2 h at room temperature. After five washes with PBS containing 0.05% Tween-20, the plates were incubated with 50 µl of goat anti-human IgG antibody conjugated with horseradish peroxidase (SouthernBiotech) at room temperature for 2 h. Following five washes with PBS containing 0.05% Tween-20, bound reactants were developed with 50 µl of 50 µg/ml 2,2'-azinobis diammonium salt (Pierce) in citrate-phosphate buffer (pH 4.0; 0.2M Na2HPO4, 0.1M citrate, 1.0 ìl/10 ml of 30% H2O2). The absorbance was determined at 405 nm.
Eyes were immediately removed and immersed in a cold fixative of 4% glutaraldehyde in 0.1 M phosphate buffer. Corneas were removed and the eyes left in fixative for 24 h. The lens was then removed, followed by dehydration with a graded series of increasing ethanol concentrations. Eyecups were embedded in an Epon mixture. For each sample, 0.5 µm-thin sections were stained with toluidine blue for light microscopy.
Frozen sections were obtained from retina embedded in Optimal Cutting Temperature (OCT; Tissue-Tek; Miles Inc., Elkhart, IN). Sections were blocked for non-specific protein-binding with 3% BSA in PBS at room temperature for 1 h and then incubated with the first antibody for 2 h at room temperature in PBS containing 3% BSA. After washing with PBS+0.2% Triton X-100 (room temperature, 3×10 min), the sections were incubated with the fluorescence-conjugated secondary antibody in PBS+3% BSA. They were then counterstained with 4',6-diamidino-2-phenylindole (DAPI; 0.3 µM) before observation with a fluorescence microscope (Olympus, Tokyo, Japan). The anti-glial fibrillary acidic protein (GFAP) antibody (1:500 dilution) was from Abcam (Cambridge, MA), the anti-rhodopsin (1:500 dilution), anti-S-opsin, and anti-calretinin antibodies (1:500 dilution) were from Millipore (Billerica, MA), the anti PKC-α antibody was from Sigma (St. Louis, MO), and the anti-C1q and anti-C3 antibodies (1:500 dilution) were from Cederlane (Burlington, NC).
White blood cells and macrophages were obtained from control and AIR mice retinas by vigorous pipetting and were centrifuged. Staining for flow cytometry was performed within 24 h. Briefly, fluorochrome-conjugated mAbs were added to cells (1 µg/106 cells). These were then incubated in the dark for 20 min at room temperature. Cells were washed twice with staining buffer, resuspended in Cytofix (BD Biosciences, San Jose, CA), and kept in the dark at 4 °C until cytometric analysis (within 24 h). Analysis was performed on a FACSCalibur flow cytometer (BD Biosciences). Mean fluorescent intensity (MFI) was calculated as a ratio of mean fluorescence sample/isotype fluorescence. Percentage positive expression was calculated by comparing the population of cells with increased fluorescent intensity to the following isotypes: anti-CD4, -CD8, -CD19, -CD69; anti-Ly6G antibodies were from BD Biosciences and the anti-mouse CD68 antibody (1:500 dilution) was from Fisher Scientific (Pittsburgh, PA).
The student t-test was employed for the statistical analysis. Statistical significance was defined as p<0.05. All data were presented as mean±SD.
We first purified the recombinant recoverin using a Phenyl Sepharose 6 Fast Flow column. The purity of recoverin was confirmed by SDS–PAGE analyses of the supernatant during the recoverin purification process (Figure 1A) and the purified recombinant recoverin was confirmed by immunoblotting (Figure 1B). We also generated recoverin monoclonal antibody-producing hybridoma cells and then injected the cells intraperitoneally in five-month old balb/cJ mice. Ascites formed after about 10 days  and the ascitic fluid was withdrawn to test the recoverin antibody level (Figure 1C).
To test whether pathologic retinopathy could be generated by immunizing recoverin in-C57BL/6J mice and B6.MRL-Faslpr/J (LPR) mice, we initially challenged six-week-old mice with 50 µg recoverin intraperitoneally and repeated this two more times over eight weeks, at which time the antibody levels were tested. Anti-recoverin antibody levels were significantly increased in recoverin-immunized LPR mice compared to control LPR mice (p<0.05), while the antibody titer was ~2 times higher in recoverin-sensitized LPR mice compared to recoverin-sensitized C57BL/6J mice (Figure 2). Similar results were found in the immunoblotting analysis (Figure 2). These data indicate higher anti-recoverin antibody levels can be achieved in LPR mice than in C57BL/6J mice using the same methodology. Electroretinogram recordings were used to determine whether immunization with recoverin affects the retinal function in C57BL/6J and LPR mice. However, small but significant electroretinographic changes (p<0.05) in recoverin-immunized C57BL/6J mice were observed in the scotopic, photopic, and maximum responses compared to control C57BL/6J mice (Figure 2). However, degeneration was not detected upon histology and the ERG changes in the immunized C57BL/6J mice revealed a small physiologic effect of the autoantibodies. By comparison, the histologic changes in the LPR mice suggest that higher elevations of anti-recoverin antibodies are needed to elicit disease. However, the ERG amplitudes of recoverin-immunized mice for the scotopic, photopic, and maximum electroretinographic responses were significantly reduced by ~35% compared with control LPR mice (Figure 2, Figure 3; inset table in Figure 3).
We also injected the recoverin hybridoma cells intraperitoneally in five-month old balb/cJ mice. Ascites formed after about 10 days and the ascitic fluid was withdrawn to test the recoverin antibody level (Figure 1C); the ERG was also tested. Both b- and a-wave amplitudes in scotopic electroretinographic responses were reduced by about 50% in mice who received sham intraperitoneal injections compared to control balb/cJ mice; b-wave amplitudes in photopic electroretinographic responses were reduced by ~40% (Figure 3).
After LPR mice were sensitized with recoverin three times, we evaluated the mouse eyes using biomicroscopy (25×) and indirect retinoscopy; there were no cells in the aqueous or vitreous, which excluded active uveitis. The eyes were then enucleated for histopathologic analysis two weeks after the last immunization. In the recoverin-sensitized LPR mice, H&E staining showed cell body swelling throughout the inner nuclear layer (INL) and migrating cells between the INL and ganglion cell layer (GCL) were also observed (Figure 4). In LPR-sensitized mice, GFAP staining demonstrated
Mueller and astrocyte swelling and increased numbers in the INL and GCL compared to normal controls (Figure 5; GFAP). Rhodopsin and S-opsin expression were not altered in either group, while bipolar cells (stained with protein kinase C-α antibodies) were decreased in recoverin-immunized LPR mice (Figure 5). Although amacrine cells showed no change, the interplexiform layer (IPL) was thinned compared to controls.
H&E staining from hybridoma-injected balb/cJ mice showed photoreceptor and outer nuclear layer (ONL) thickening that was uneven in distribution (Figure 4), as well as migrating cells between the INL and GCL. Glial fibrillary acidic protein staining showed a remarkable increase in astrocyte and glial staining from the INL to the GCL (Figure 5). Rhodopsin and S-opsin expression were not altered in either group, while bipolar cells (PKC-α) were decreased in the hybridoma-injected balb/cJ mice. Amacrine cells were not changed, but the IPL was noticeably thinned. (Figure 5)
The complement system is known to participate in a variety of ocular diseases, including macular degeneration and uveitis [24,25]. Complement components contribute to pathogenic processes by damaging the tissue and stimulating chemotaxis and in age-related macular degeneration (AMD) are known to facilitate neovascularization. C1q is able to directly bind to apoptotic cells via its globular head domains, which may induce complement activation with subsequent opsonization of C4b and C3b to the surface of apoptotic cells . To test if complement components were involved in the mechanism of our two recoverin-associated AIR mouse models, we stained for C1q and C3.
Immunohistochemical analyses showed that compared with control LPR mice, scattered C1q deposits were observed in the retinal pigment epithelium (RPE), INL, and GCL of recoverin-immunized LPR mice (Figure 6). No sections of the control LPR mice exhibited C1q deposits in the retina (Figure 6). Although there were C3 deposits in the RPE of control LPR mice (Figure 6), C3 deposits were remarkably increased in the RPE layer in recoverin-immunized LPR mice and scattered C3 deposits were found in the INL and GCL (Figure 6). CD3+ cells were observed between the INL and GCL layers, and the migrating cells between INL and GCL were CD3+ cells (Figure 6). CD68+ cells were found in the IPL and OPL in recoverin-immunized LPR mice retina (Figure 6).
Immunohistologic microscopy showed that compared with control balb/cJ mice, very few scattered C1q deposits were found in the RPE, INL, and GCL of recoverin monoclonal antibody-producing hybridoma cells injected in the balb/cJ mice (Figure 6). There was no C1q immunostaining in control balb/cJ mice. The staining for C3 deposits was remarkably increased in the RPE layer in recoverin monoclonal antibody producing hybridoma cells injected into balb/cJ mice compared to control mice; scattered C3 deposits in the INL and GCL were also seen. (Figure 6). The migrating cells between the INL and GCL were CD3+ cells (Figure 6), and CD68+ cells were found in the RPE and OPL of the retinas of Balb/c mice injected with recoverin hybridoma cells (Figure 6).
Flow cytometry analysis of CD 68 (macrophage marker) showed increased levels of CD68 positive cells (0.07%) in the retinas of recoverin-immunized LPR mice compared to control LPR mice (0.03%) (Figure 7). CD3 positive cells increased (0.1%) in the retinas of recoverin-immunized LPR mice compared to those of control LPR mice (0.02%). There were no Ly6G positive cells, CD8 positive cells, or CD19 positive cells observed in either group.
Although AIR has been identified for over 15 years, an animal model of this disease has not been available. Animal models, and particularly mice with identical or very similar hereditary disorders to man, have proven to be a powerful investigative tool for understanding cellular, molecular, and degenerative mechanisms in retinal degeneration. With these two AIR models it will be possible to provide new information about the pathophysiology of AIR, specifically looking at inflammatory mechanisms in the retina and testing different putative pathologic retinal antigens known to be associated with AIR. In this study, we described two mouse models with immunologically induced retinopathy associated with elevated recoverin antibodies; both models had attenuated scotopic and photopic ERGs, retinal thinning, accelerated C1q and C3 deposits in the retinas, enhanced expression of GFAP staining identifying a reactive gliosis, and infiltration of inflammatory cells, including macrophages and neutrophils.
Sixty-five percent of patients with AIR have a family history of other autoimmune disorders (e.g., rheumatoid arthritis, lupus, thyroid disease, asthma) and having an autoimmune genetic background seems to make some patients more susceptible to AIR . The recoverin-immunized LPR mice showed moderate retinal degeneration that was not found in the recoverin-immunized C57BL/6J mice (with no autoimmune genetic background), similar to the pattern seen in human AIR. Here, we only tested one retinal antigen to stimulate antibody formation, while AIR patients normally have multiple immunoreactive bands from circulating anti-retinal antibodies on western blot testing. Identification of the underlying antigenic proteins in AIR has been slow, and only a few of the many antibodies found in AIR patients have been proven to cause retinal damage or degeneration. Most immunoreactive bands (i.e., antibodies) from AIR patients have not been investigated and their antigenic stimuli have yet to be identified.
Recoverin has been proven to be a cause of AIR [3,10,12,13]. A rat model system has been established to elucidate the contribution of recoverin autoantibodies to the development of retinopathy . The injection of recoverin has led to the induction of uveitis and retinal degeneration. In a guinea pig model, animals were sensitized with small cell lung cancer cell lines that induced production of anti-recoverin autoantibodies in the animals and caused retinopathy . In an experimental BALB/c mouse model, Maeda et al. induced specific cytotoxic T lymphocytes in response to the peptide R64 (AYQHVFRSF) and observed a tumor-preventive effect; however, this peptide also induced the generation of antibodies and retinal degeneration . Our two mouse models have elevated circulating anti-recoverin antibodies, which is a feature observed in AIR patients, especially CAR patients. In other studies, anti-recoverin autoantibodies induced apoptosis in photoreceptor and bipolar cells, leading to retinal degeneration [29,30]. We did not observe apoptotic cells in these two models (data not shown), but we only looked at one time point after the disease was clearly present on the ERG. Serial Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and autophagy studies will be needed in the future to further investigate this issue. It is unclear why the blood-retinal barrier does not prevent autoantibodies from penetrating into the retina, but leukostasis or leukocyte deposits (focal vascular staining ) on retinal vessel walls seen in AIR patients may damage the tight junctions and allow immunoglobulin diffusion [31,32].
One of the more important findings of this study was the striking reactive retinal gliosis and infiltration by leukocytes found in both models. Differential changes in the GFAP expression in Mueller glial cells is the most sensitive nonspecific response to retinal diseases and injuries and has been used as a universal early cellular marker for retinal injury . The finding of inflammatory cells on retinal histopathology and flow cytometry in our two mouse models is consistent with recent case reports of AIR in systemic lupus erythematosus. Macrophages were seen in the retina, particularly in areas of photoreceptor degeneration . Activation of infiltrating macrophages and granulocytes causes destruction of the retina by the release of reactive oxygen species, including nitric oxide (NO) and superoxide . Humans with AIR do not have cells or flare in the anterior chamber and seldom show obvious clinical infiltration of the retina, although cystoid edema and retinal wrinkling are commonly found . White retinal patches are seldom a feature in AIR. The new finding of a gliotic cellular response and infiltration of retinas by inflammatory cells without uveitis is important and is likely to bear on the pathologic degenerative mechanisms seen in AIR.
The complement system is involved in antigen-specific immune responses, with an identified role in antigen processing and presentation, T-cell proliferation and differentiation, and B-cell activation . Complement activation products such as C3 have been shown to be present in the eyes of patients with autoimmune uveitis  and in drusen in patients with age-related macular degeneration . Our two mouse models show elevated C1q and C3 deposition in the RPE and INL of retinas. The complement components may enhance the damage initiated by the pathogenic process. These preliminary results suggest further investigation is needed to determine the role of the complement system in AIR.
Two successful mouse models for AIR were generated by our experimental approaches, both using alternate methods of producing anti-recoverin antibodies. These models not only will be important for understanding the pathogenesis and mechanisms involved in human AIR, but will also be valuable for testing potential therapies. The pathologic changes in anti-recoverin antibodies were not as severe as we had expected, which may suggest that a mixture of retinal antibodies may be the cause of the varying clinical severity seen in AIR patients who typically have multiple ARAs.
This work was supported by Foundation Fighting Blindness, and NIH grant R01 EY007758. This work used hybridoma Core of the Michigan Diabetes Research and TrainingCenter funded by DK020572 from the National Institute of Diabetes and Digestive and Kidney Diseases.We gratefully acknowledge the discussions and help of Dr. Raymond Douglas of University of Michigan, Dr. David Serreze and Norman Hawes of The Jackson Laboratory, and the donation of the recoverin construct by Dr. James Hurley of University of Washington.